Limited coverage drugs – deferiprone

Last updated on October 7, 2022

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	deferiprone
Strength	100 mg/mL, 1000 mg
Form	oral solution, tablet

Special Authority criteria	Approval period
Treatment of transfusion-dependent iron overload due to thalassemia syndromes, where iron chelation therapy is required, according to established criteria*, and when prescribed by a hematologist.	Initial request: 1 year Renewal request: 1 year

Special Authority criteria

Approval period

Treatment of transfusion-dependent iron overload due to thalassemia syndromes, where iron chelation therapy is required, according to established criteria*, and when prescribed by a hematologist.

Initial request: 1 year

Renewal request: 1 year

Practitioner exemptions

None

Special notes

None

Special Authority request form(s)

* Click on the Special Authority Form below for full criteria:

Log in to eForms
5407 - Deferiprone Coverage - Initial and Renewal (PDF, 360KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – deferiprone

Practitioner exemptions

Special notes

Special Authority request form(s)